Imprese · 23/09/20241 min di lettura
Progynon Associates, et al.; Withdrawal of Approval of Four New Drug Applications
Traduzione automatica locale · Lingua originale della fonte
Riepilogo
The Food and Drug Administration (FDA) is withdrawing approval of four new drug applications (NDAs) from multiple holders of those NDAs. The basis for the withdrawal is that these NDA holders have repeatedly failed to file required annual reports for the identified NDAs.